$AUPH long term investor with about 110,000 shares....Voclosporin for treatment of LN is undoubtedly protected through the end of 2037, label will be very specific within the parameters of the dosing patent, a patent which mirrors the dosing protocol of phase 2 and 3, LN is a highly deadly disease- FDA will not provide approval without including the dosing protocol covered by the dosing patent, BO will happen after FDA approval confirms these details with their approval patents.google.com/patent/U...
  • 20
20 Likes